1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical Contract Sales Outsourcing (CSO) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Service
8.1.1. Personal Promotion
8.1.1.1. Market Revenue and Forecast
8.1.2. Non-personal Promotion
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Therapeutic Area
9.1.1. Cardiovascular Disorders
9.1.1.1. Market Revenue and Forecast
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast
9.1.3. Metabolic Disorders
9.1.3.1. Market Revenue and Forecast
9.1.4. Neurology
9.1.4.1. Market Revenue and Forecast
9.1.5. Orthopedic Diseases
9.1.5.1. Market Revenue and Forecast
9.1.6. Infectious Diseases
9.1.6.1. Market Revenue and Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service
10.1.2. Market Revenue and Forecast, by Therapeutic Area
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service
10.2.2. Market Revenue and Forecast, by Therapeutic Area
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service
10.3.2. Market Revenue and Forecast, by Therapeutic Area
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service
10.4.2. Market Revenue and Forecast, by Therapeutic Area
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service
10.5.2. Market Revenue and Forecast, by Therapeutic Area
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area
11.1. IQVIA Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Syneos Health Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Parexel International Corporation
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pharmaceutical Product Development (PPD) LLC
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. inVentiv Health Inc. (part of Syneos Health)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. ICON plc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Publicis Touchpoint Solutions, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. PRA Health Sciences, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. The Medical Affairs Company (TMAC)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Ashfield Healthcare Communications Group (part of UDG Healthcare plc)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
